VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

S. pneumoniae RASV synthesizing PsaA
Vaccine Information
  • Vaccine Name: S. pneumoniae RASV synthesizing PsaA
  • Target Pathogen: Streptococcus pneumoniae
  • Target Disease: Pneumonia
  • Vaccine Ontology ID: VO_0004071
  • Type: Recombinant vector vaccine
  • Status: Research
  • psaA gene engineering:
    • Type: Recombinant vector construction
    • Description:
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intranasally
Host Response

Mouse Response

  • Host Strain: BALB/c, C57BL/6J
  • Vaccination Protocol: Mice were inoculated intranasally with 10 µl or orally with 20 µl of BSG containing 1 x 109 CFU of the RASV or control strain. In some experiments, the mice were boosted at week 6 with the same dose by using the same route as that used for primary immunization (Wang et al., 2010).
  • Challenge Protocol: At week 10, mice were challenged either by intraperitoneal injection with 2 x 104 CFU of S. pneumoniae WU2 (equal to 100x the 50% lethal dose [LD50]) or intranasally with 20 µl containing 5 x 106 CFU S. pneumoniae strain L82016 or E134 or 1 x 107 CFU of strain A66.1 or D39 (Wang et al., 2010).
  • Efficacy: BALB/c (haplotype H2(d)) or C57BL/6 (haplotype H2(b)) mice vaccinated either orally or intranasally exhibited a significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with S. pneumoniae strains compared to controls, although protection was not observed with all challenge strains (Wang et al., 2010).
References
Wang et al., 2010: Wang S, Li Y, Shi H, Scarpellini G, Torres-Escobar A, Roland KL, Curtiss R 3rd. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infection and immunity. 2010; 78(7); 3258-3271. [PubMed: 20479086].